Author: ST Staff

The stock of SPI Energy Co., Ltd. (SPI) saw a gain in the Pre-market. The stock reached $7.27 ‎by increasing 0.28% in the Pre-market. In the last trading session, the stock closed at $7.25 which ‎is a 17.89% gain in just a single day. The total volume of the stock traded in the market was ‎‎786.71K. There are mainly two reasons which could be linked to this uprise in the stock which ‎we will see in the following details.‎

Two main reasons for the SPI Energy Co., Ltd. (SPI) stock gain:‎

After the IPO by Rivian (NASDAQ: RIVN) and the positive news from the Electric Vehicle ‎Companies, made investors not ignore the EV stocks. Due to this boom, the shares of SPI ‎Energy Co., Ltd. (SPI) are taking advantage of it. After which the stock of the SPI gained ‎a value of 17% before closing. Also, the trading volume was seen to be 10 times more than the ‎daily average trading volume of its company’s stock.‎

So why this affected the SPI Energy Co., Ltd. (SPI) stock to gain value? The reason is, investors ‎are interested in its company’s stock due to EdisonFuture, which is a subsidiary of SPI Energy ‎who is introducing its debut electric truck named EF1-T e-pickup Truck. The USP (unique ‎selling proposition) of this EV truck is, it will be able to charge by solar energy. So this means it ‎will be able to charge itself while under the sun.

Another reason for this increase in the stock could be related to the issue of a $4.21 million 10% ‎convertible promissory note on 12th November 2021 to StreetervilleCapital, LLC.

The board of directors of SPI approved this convertible promissory note that bears interest at the ‎rate of 10% per year. The maturity date of this convertible promissory note is set to be 11 ‎November 2022.

Conclusion

After the news hit the market, the stock of SPI Energy Co., Ltd. (SPI) saw a positive trend, and ‎investors seemed to be taking a serious interest in its stock. The debut of the electric trucks by its ‎subsidiary company kept the investors hooked and are likely to positively affect the stock of the ‎company in the upcoming days.

The shares of Atea Pharmaceuticals, Inc. (AVIR) stock saw a decline in the after-hours. The stock declined by 11.44% to reach $10.06. The trading volume of the shares in the market was 7.25 Million. In the previous trading session the stock closed at $11.36. The reason of this decline could be linked to the canceling of the partnership by Roche with Atea to develop Covid-19 antiviral pill.

Reasons of Roche Holding AG (ROG) walking away from partnership with Atea Pharmaceuticals, Inc. (AVIR):

On November 16, 2021 Roche Holdings AG announced that they are cancelling the partnership with Atea Pharmaceuticals after they joined last year together to develop an oral pill named AT-527 for which Atea received an upfront cash of $350 million.

But after continuous efforts by Atea the treatment did not show as promising result as it should have in the reduction of viral disease in the all categories of patients with mild or moderate Covid-19 in the month of October.

However the rights of AT-527 will be returned to the company Atea as the joint venture ends in the month of February 2022. The Atea said they will continue their efforts in regards to the dvelopement of the treatment.

Financial highlights of Atea Pharmaceuticals:

The company also announced their financial report of third quarter. Here is the overview of their 3^rd quarter financials:

• Collaboration revenue for the 3^rd quarter was $38.2 million. All the collaboration revenue came from the Roche agreement which started in October 2020.
• R&D expenses were $43 million. This increased from $13.6 million by $29.4 million for the quarter ended in September 2021.
• Net loss for the 3^rd quarter of 2021 was $28.2 million. Last year the loss in the same quarter was $17.6 million. It increased by $10.6 million.

Conclusion:

Atea Pharmaceuticals, Inc. (AVIR)says that the company will continue the development on their own. They have enough financial resources to carry out the process on their own. They say Atea have cash and cash substitutes that are equivalent to $839.7 million as of 30 September 2021. They will forward the development on AT-527 until they reach to some productive conclusion.

Bit Brother Limited (NASDAQ: BTB) serves as a chemical manufacturer, which usually involves in the manufacture and distribution of organic compounds. The company contains PCT/OCT downstream products which are used for pharmaceuticals, agrochemical, dye and other related items. Revenue for the company comes from the stores being directly operated. Having a market capitalization of 93.77 Million dollars, it is considered as a Micro-cap (penny) stock at NASDAQ.

Penny stock (Movers)  – Day traders first love?

BTB: Technicals

As far as stock technical are concerned, BTB is highly volatile in price volume comparison. It readily affects any external news impacting the nature of business of Bit Brothers. It has shown a wavy pattern in the chart which indicates the volume of stock being traded in the index. The buy range would be below 2.0 USD for short term trade. Profit takings should be done at each resistance level. The short term price movement suggests between 1.8-2.5 USD.

BTB: Beta & Trader’s & Invetor’s Interest

Apparently, Beta of this stock has reached to 1.35 (5Y monthly) which indicates the price variance as compared to overall index fluctuation. It seems to be a trader’s friendly stock as the volume has ticked around 76.05 Million shares as on today. One would buy this stock at each dip (considering the trend) and should realize profits at the peak level. Short sellers should play an active role in the behavior of this stock. As far as investor is concerned, one should avoid it or hold the share until it hits its 52  week high.

BTB: News Impact

Recently, company has complied the Nasdaq minimum bid price requirements therefore closing bid price reached to 1 USD which shall be implemented from October 20 to Novemeber 2, 2021.

The press release has also shown some forward looking statements which involves some assumptions so company’s actual results may differ materially from the forward statements. Few months before, direct offerings (15 Million ordinary shares & warrants at excise price of 1.5 USD per share) has been announced by Bit Brothers limited which resulted to a price drop. All such news plays a pivotal role in the stock price movement.

BTB: Fundamentals & Recommendation

The company has enough cash (698 Million USD) which seems to enough to tackle liquidity issues. Last year, Earnings are in negative (42.64) which resulted due to pandemic situations. From 2017, company has recovered its earnings and profitable earnings can be seen in near future (EPS growth rate is 54.8%). The adjusted PEG is in negative (-0.67).

Royalty Pharma Plc (NASDAQ: RPRX), being a renowned name in the biopharma companies which work with institutional conducting research, inventors, seems to be a range bound stock in the last couple of week at NADAQ. Company envision a rich 150+ years’ experience in the industry, therefore a defensive investor must keep an eye on it

Growth Stock – Keep a Bird’s Eye View at RPRX

RPRX: Technicals

RPRX shown a range bound between 38 to 41 USD in the 1M chart. This implies the phase of accumulation with volume in the stock. One must show resistance and buy on dips as company will show the uptrend in near future if this behavior continues. Average 2.3 Million share volume indicates the trust and confidence of investors and traders. Day traders can make some profit by profit taking at the month end. Forecast Earnings suggest that it would hit its all-time high in next quarter.

RPRX: Portfolio & Engagement

The company is the buyer of pharmaceutical royalties and proves to be a funding source for biopharmaceutical industry. It has accumulated a portfolio of royalties which give them payments to the industry leading sales of renowned products like Abbvie, astellas, Johnson & Johnson’s Imbruvica. Company believes to provide enough capital to the biopharmaceutical ecosystem that supports innovation and human health in near future.

RPRX provides royalty monetization to the entities where innovation is highly expanded. It is created from the drug development which includes relative science which ultimately becomes a medication to pharma companies.

RPRX: Financials

At a glance, Royalty Pharma has performed well in the recent quarters where the company has increased the retained earnings to 2,321k USD. It has also expanded its investment in the associated companies. Cash has also been increased gradually which entitles to good liquidity position.

Income statement shows a steady increase in revenue, however pretax charges caused the net income to decrease significantly. Ultimately EPS clocked at 1.32. Company has acquired more fixed assets in this year as compared to last few years. This indicates the economic activity would play an active part in the company’s profitability. Overall, the company is in expansion phase, however it has taken long term borrowings but it won’t affect much in the company’s solvency.

The Talkspace, Inc. (TALK) stock significantly declined in the after-hours. The Talkspace stock dropped by 16.22% with respect to its previous close to reach $2.84. Previously, the stock closed at $3.39. The number of shares that were traded are 651.56K. Here we will discuss some facts which triggered the decline.

The stock went down as the two Co-Founders of Talkspace, Inc. (TALK) stepped down two significant roles:

The CEO and co-founder of Talkspace, Inc. (TALK) Oren Frank have announced that he is stepping down from the roles as the CEO and board member of the board of Talkspace, Inc. (TALK). Also, the other co-founder and head of clinical services, Roni Frank also announced to step down from her position. As the news hit the market, Talkspace, Inc. (TALK) stocks lost 16.22% at the current time of this writing.

Financial overview of their third quarter:

Although their third quarter was not bad in terms of numbers, the sudden stepping down of the two co-founders really had a significant effect on the share price in the market. Some of the key highlights of their third-quarter are:

• The increase of 23% in the revenue was witnessed over the prior-year period. The net revenue for the third quarter was $26.4 million.
• Gross profit saw a decline due to some increase in the reserve for the losses in credit on receivables. The third-quarter gross margin is $14.2 million while in the prior-year quarter it was $15.1 million. This sums up as 54% Gross profit as compared to 70% over a year ago.
• The total net income was $1.5 million. This was a positive number as compared to a loss of -$2.7 million in the prior-year period.
• Talkspace, Inc. (TALK) adjusted EBITDA loss of ($20.8) million in the third quarter as compared to ($2.0) million in the prior-year period.

Key milestones achieved in the third quarter:

• The total number of responsive members saw an increase of 21% year-over-year to almost 60,300.
• As of September 30, 2021, the B2B eligible lives grow by 92% year-over-year to more than 75 million.
• B2B sessions increased by 96%. The number of completed B2B sessions was 71,300.

Conclusion:

Talkspace, Inc. (TALK) has an interim CEO right now and is looking for a permanent candidate for the position. Whoever will they select for the job will have an impact on the stock of Talkspace, Inc. (TALK).